33 patents currently held

2 more in force are now held by other companies

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Feb 2030. from the record

Free plan: 3 watched companies. Pro: unlimited.

Alerts on its grants, lapses and transfers.

Ending by 2030

Feb 2030

Next term end

Patent families

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036 2037 2038 2039204020412042 2043 2044 2045

notable patents fee due within 90 days all others Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank

Notable

Non-naturally occurring T cell receptors US 8,519,100

The most cited patent in this portfolio, cited by 57 later US patents, top 10% of utility patents granted in 2013 in our data. Protection runs to 2030.

Ends Jul 2030 · High confidence Also notable

Bifunctional Polypeptides US 10,130,721

Cited by 14 later US patents, top 25% of utility patents granted in 2018 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2030. A terminal disclaimer caps this term to an earlier patent's.

Ends Jul 2030 · High confidence Also notable

Peptides Derived from Kita-Kyushu Lung Cancer Antigen (KKLC1, CT83, CXORF61) and Complexes Comprising Such Peptides Bound to MHC Molecules US 10,835,577

Cited by 10 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2037.

Ends Mar 2037 · High confidence

Formerly held, still cited

Notable

Modified T Cell Receptors and Related Materials and Methods US 8,088,379

The most cited patent in this portfolio, cited by 109 later US patents, top 5% of utility patents granted in 2012 in our data. Protection runs to 2028.

now held by Adaptimmune Limited

Ends Mar 2028 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Dec 30, 2026
The maintenance fee for Nucleic Acid Molecules Encoding Non-Naturally Occurring T Cell Receptors and Cells Thereof (US 9,068,178) comes due Dec 30, 2026. Unpaid by Jun 30, 2027, it lapses early.
3 fees due Feb 8 to 28, 2027 · next Feb 8
1 fee due Mar 24, 2027
The maintenance fee for Bifunctional Polypeptides (US 10,420,846) comes due Mar 24, 2027. Unpaid by Sep 24, 2027, it lapses early.
1 fee due May 28, 2027
The maintenance fee for Dosing Regimen for GP100-Specific TCR - ANTI-CD3 SCFV Fusion Protein (US 11,827,688) comes due May 28, 2027. Unpaid by Nov 29, 2027, it lapses early.
1 fee due Jun 30, 2027
The maintenance fee for Bifunctional Polypeptides (US 10,517,960) comes due Jun 30, 2027. Unpaid by Jan 3, 2028, it lapses early.
2 fees due Sep 3 to 12, 2027 · next Sep 3

Which patents, and when each one lapses · Pro

Recent changes

Oct 26Assignment recorded on 1 record: Chillakuri, Chandramouli and 3 others to Immunocore Limited Recorded Oct 26, 2026, executed Aug 20, 2026. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76498, frame 321.
Oct 9Assignment recorded on 1 record: Chillakuri, Chandramouli and 1 other to Immunocore Limited Recorded Oct 9, 2026, executed Aug 26, 2026. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76320, frame 547.
1 of the patents on this record was granted since Aug 16, 2026

What they patent

The 5 largest of its 20 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Bifunctional Polypeptides	4 in force	to Jul 2030
T Cell Receptors (2019)	3 in force	to Nov 2038
Peptides Derived from Actin-Like Protein 8 (ACTL8)	3 in force	to May 2037
T Cell Receptors (2018)	2 in force	to May 2039
Engineered Immune-Mobilizing T-Cell Receptors with Enhanced Affinity for HIV-1 Gag	2 in force	to Mar 2039

Patents held now

Soonest term end first.

Patent	Title	Status	Expires	Confidence
US 8,361,794	Cells Expressing a Modified T Cell Receptor In force Term ends Feb 18, 2030 · High confidence	In force	Term ends Feb 18, 2030	High confidence
US 10,420,846	Bifunctional Polypeptides In force Term ends May 19, 2030 · High confidence	In force	Term ends May 19, 2030	High confidence
US 10,517,960	Bifunctional Polypeptides In force Term ends May 19, 2030 · High confidence	In force	Term ends May 19, 2030	High confidence
US 10,576,162	Bifunctional Polypeptides In force Term ends May 19, 2030 · High confidence	In force	Term ends May 19, 2030	High confidence
US 8,519,100	Non-naturally occurring T cell receptors In force Term ends Jul 1, 2030 · High confidence	In force	Term ends Jul 1, 2030	High confidence
US 9,068,178	Nucleic Acid Molecules Encoding Non-Naturally Occurring T Cell Receptors and Cells Thereof In force Term ends Jul 1, 2030 · High confidence	In force	Term ends Jul 1, 2030	High confidence
US 10,130,721	Bifunctional Polypeptides In force Term ends Jul 1, 2030 · High confidence	In force	Term ends Jul 1, 2030	High confidence
US 11,017,882	Method for Predicting the Off-Target Biding of a Peptide Which Binds to a Target Peptide Presented by a Major Histocompatibility Complex held by Immunocore Limited and Adaptimmune Limited In force Term ends Dec 17, 2033 · High confidence	In force	Term ends Dec 17, 2033	High confidence
US 11,929,151	Method for Predicting the Off-Target Binding of a Peptide Which Binds to a Target Peptide Presented by a Major Histocompatibility Complex held by Immunocore Limited and Adaptimmune Limited In force Term ends Dec 17, 2033 · High confidence	In force	Term ends Dec 17, 2033	High confidence
US 11,124,556	TCR Libraries In force Term ends Sep 15, 2036 · High confidence	In force	Term ends Sep 15, 2036	High confidence

10 of 33 patents shown.

Pro members see all 33.

Pro members: see all 33 patents

Also on record, not counted in the 33: 2 patents in force now held by others · 18 patents ended · 29 applications pending · 87 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built

Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.

Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Immunocore Limited